Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Opko Health Acquires NK-1 Compounds From Schering
Opko Health has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co (Schering). Rolapitant, a neurokinin-1 (NK-1) receptor antagonist,
Opko Health has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co (Schering). Rolapitant, a neurokinin-1 (NK-1) receptor antagonist,
Nuvo Research’s German subsidiary Dimethaid has entered into a new licensing agreement with Ranbaxy for Oxoferin. The company has also reported an additional funding assistance, which willbe provided
Sanofi Pasteur has reported the final analyses of data from clinical trials of the US licensed Influenza A (H1N1) 2009 Monovalent Vaccine in adults and children. Reportedly, the
Geron has presented new data showing that oligodendrocyte progenitor cells (OPCs) derived from human embryonic stem cells (hESCs), when transplanted into a rodent model of cervical spinal cord
Theratechnologies has presented the results from both its Phase 3 clinical trials evaluating Tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. In addition,
Amarillo Biosciences (ABI) has reported that a Phase 2 clinical trial of ABI’s low-dose oral interferon is ongoing in Australia in 200 healthy human volunteers exposed to the
LecTec has reached a settlement with Endo Pharmaceuticals on outstanding patent litigation related to LecTec’s US Patent Nos 5536263 and 5741510. Endo Pharmaceuticals has agreed to make a
Endo Pharmaceuticals has agreed to make a one-time, $23m payment for the exclusive license to these two patents for use in the field of prescription pain medicines and
Vivakor has completed a distribution agreement with consumer product specialist, Regeneca International for one of its proprietary, nutraceutical formulations. In conjunction with this agreement was an immediate purchase
CSL Biotherapies has received FDA approval for its seasonal flu vaccine, Afluria (Influenza Virus Vaccine) for use in the pediatric population aged 6 months and older. This approval